2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share

2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share

The biotech company expects to report data from phase 3 studies of its coronavirus vaccine candidate in the coming weeks. The troubles of rivals AstraZeneca (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) offer CureVac an opportunity to become a leader in Europe. Several European countries temporarily suspended use of the AstraZeneca vaccine last month after some vaccinated individuals developed blood clots.